Barclays PLC Arcturus Therapeutics Holdings Inc. Transaction History
Barclays PLC
- $353 Billion
- Q1 2025
A detailed history of Barclays PLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Barclays PLC holds 47,527 shares of ARCT stock, worth $595,513. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,527
Previous 60,082
20.9%
Holding current value
$595,513
Previous $1.02 Million
50.69%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding ARCT
# of Institutions
161Shares Held
26.5MCall Options Held
312KPut Options Held
96.5K-
Federated Hermes, Inc. Pittsburgh, PA4.69MShares$58.8 Million0.11% of portfolio
-
Black Rock Inc. New York, NY2.65MShares$33.2 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.01MShares$25.2 Million0.23% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.1.93MShares$24.1 Million0.01% of portfolio
-
Nikko Asset Management Americas, Inc.1.93MShares$24.1 Million0.27% of portfolio
About Arcturus Therapeutics Holdings Inc.
- Ticker ARCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,576,400
- Market Cap $333M
- Description
- Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...